Novavax CEO to Present at BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 7 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) Chief Executive Officer Dr. Rahul Singhvi will present at the BIO CEO & Investor Conference at 12:45 p.m. on Feb. 13 at The Waldorf=Astoria Hotel in New York, the company announced today.
Dr. Singhvi will provide an overview of the company's strategy, research and development progress and strategic partnerships. A link to an audio webcast of his presentation will be available at 12:45 p.m. Eastern time on Tuesday, Feb. 13, through the company's website, http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 30 days.
Novavax Inc. (Nasdaq: NVAX) is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
SOURCE Novavax Inc.
CONTACT: Mariann Caprino, Novavax Inc.,